Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bills Calling For Non-Pharma Alternatives To Opioids Clear US House

Executive Summary

Several bills that try to lift barriers to development and use of device alternatives for pain management in response to the opioid crisis were recently approved by the US House.

You may also be interested in...



Payment 'Sunshine' Requirements Would Expand For Industry Under Senate-Passed Opioid Bill

A provision to expand Sunshine Act industry reporting requirements for companies in the Senate-passed “Opioid Crisis Response Act” has caught criticism from the device sector, despite overall industry support for the legislation.

Bills Supporting Device Opioid Alternatives Advance In House

The House Energy and Commerce Committee approved four opioid crisis-related bills that call for US FDA meetings and consideration of streamlined pathways for medtech alternatives to opioids, and for a report and action by the US Medicare agency on overcoming payment challenges to device pain control products.

Advancing Bill Would Require Medicare Plans To Highlight Device Opioid Alternatives

The House Energy and Commerce Committee on May 9 approved, and sent to the full chamber, a bill requiring Medicare Part D drug plans to highlight information for prescribers on covered non-opioid pain devices and alternative medications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel